Cresco Labs (CRLBF) Non-Current Debt (2019 - 2026)
Cresco Labs (CRLBF) posted Non-Current Debt of $418.2 million for Q1 2026, little changed on a QoQ basis from $417.1 million in Q4 2025.
Cresco Labs (CRLBF) Non-Current Debt (2019 - 2026) Analysis & Trends
Cresco Labs' Non-Current Debt history runs 8 years deep, the most recent figure standing at $418.2 million for Q1 2026.
- Quarterly Non-Current Debt changed N/A year-over-year to $418.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $418.2 million (changed N/A YoY) and the FY2025 annual result came in at $417.1 million, changed N/A from the prior year.
- Non-Current Debt was $418.2 million for Q1 2026 at Cresco Labs, roughly flat from $417.1 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $499.3 million in Q3 2024 and bottomed at $417.1 million in Q4 2025.
- A 5-year average of $470.7 million and a median of $497.7 million in 2023 frame the typical range for Non-Current Debt.
- Peak annual rise in Non-Current Debt reached 80.39% in 2022, while the deepest fall reached 80.39% in 2022.
- Cresco Labs' Non-Current Debt stood at $466.1 million in 2022, then rose by 6.79% to $497.7 million in 2023, then increased by 0.33% to $499.3 million in 2024, then retreated by 16.47% to $417.1 million in 2025, then increased by 0.27% to $418.2 million in 2026.
- Business Quant data shows CRLBF's Non-Current Debt at $418.2 million in Q1 2026, $417.1 million in Q4 2025, and $499.3 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Cresco Labs | 254.96 Mn | 99.57 Mn | 75.45 Mn | 418.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 418.23 Mn |
| Dec 31, 2025 | 417.10 Mn |
| Sep 30, 2024 | 499.33 Mn |
| Jun 30, 2024 | 498.69 Mn |
| Mar 31, 2024 | 498.00 Mn |
| Dec 31, 2023 | 497.71 Mn |
| Mar 31, 2022 | 466.08 Mn |
| Dec 31, 2021 | 465.08 Mn |
| Sep 30, 2021 | 463.86 Mn |
| Mar 31, 2021 | 258.37 Mn |
| Dec 31, 2020 | 255.44 Mn |
| Dec 31, 2019 | 550,000.00 |